help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
The Oncologist, Vol. 2, No. 1, 64, February 1997
© 1997 AlphaMed Press

SPECIAL SECTION
PATIENT CARE

From The Durham Post


   ABSTRACT
Top
 Abstract
From the Durham Post
 
The Patient Care section of The Oncologist extends the opportunity for major cancer centers to enroll patients in high-priority clinical trials. If you wish to have your clinical trial(s) announced, send all pertinent details to the Executive Editor.


   From the Durham Post
Top
 Abstract
 From the Durham Post
 
The Adult and Pediatric Bone Marrow Transplant Programs of Duke University Medical Center in Durham, North Carolina, announce their clinical trials utilizing HLA Partially Mismatched Unrelated Umbilical Cord Blood Allogeneic Transplantation for patients with hematologic malignancies or marrow failure syndromes.

The first protocol is "A Pilot Study of Unrelated Umbilical Cord Blood Transplantation in Children and Adults with Hematologic Malignancies." Its objectives are:

{blacktriangleup} To determine the rates of hematologic and immune reconstitution in adult and pediatric patients with high-risk hematologic malignancies, undergoing high-dose chemo-irradiation followed by unrelated umbilical cord blood transplantation.
{blacktriangleup} To determine the incidence of graft-versus-host disease in this setting.
{blacktriangleup} To describe the incidence of relapse post-UCB transplant.

The second protocol is "A Pilot Study of Unrelated Umbilical Cord Blood Transplantation in Adults and Children with Bone Marrow Failure Syndromes or Inherited Metabolic or Hematologic Diseases." Its objectives are:

{blacktriangleup} To determine the rates of hematologic and immune reconstitution in adult and pediatric patients with marrow failure syndromes, undergoing high-dose chemotherapy followed by unrelated umbilical cord blood transplantation.
{blacktriangleup} To determine the incidence of graft-versus-host disease in this setting.

Physicians interested in more information regarding these protocols or to verify patient eligibility requirements should contact:

Adult patient referrals: Mary J. Laughlin, M.D. at telephone: 919-684-2423; fax: 919-681-6834; e-mail: laugh001{at}mc.duke.edu.

Pediatric patient referrals: Joanne Kurtzberg, M.D. at telephone: 919-684-8963; fax: 919-681-8942; e-mail: kurtz001{at}mc.duke.edu.


   FOOTNOTES
Top
 Abstract
 From the Durham Post
 
Look for our expanded coverage on clinical trials in future Patient Care sections of The Oncologist.





This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content

HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS